IOVA insider transaction filings
IOVANCE BIOTHERAPEUTICS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-12. Screen IOVA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | Kirby Daniel Gordon — Chief Commercial Officer | Option exercise (M): 10,001 @ $0 · Tax withholding (F): 2,436 @ $6.40 · Option exercise (M): 10,001 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Roche Corleen M. — Chief Financial Officer | Option exercise (M): 49,995 @ $0 · Tax withholding (F): 21,238 @ $6.21 · Option exercise (M): 49,995 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Dukes Iain D. — Director | Grant/award (A): 180,632 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Countouriotis Athena — Director | Grant/award (A): 90,316 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Puri Raj K. — Chief Regulatory Officer | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Maynard Ryan D — Director | Grant/award (A): 90,316 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | WEISER MICHAEL — Director | Grant/award (A): 90,316 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Vogt Frederick G — Interim CEO & General Counsel, Director | Option exercise (M): 15,625 @ $0 · Tax withholding (F): 6,638 @ $4.23 · Option exercise (M): 15,625 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | GRAF FINCKENSTEIN FRIEDRICH — Chief Medical Officer | Option exercise (M): 7,813 @ $0 · Tax withholding (F): 3,976 @ $4.23 · Option exercise (M): 7,813 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Puri Raj K. — Chief Regulatory Officer | Option exercise (M): 9,766 @ $0 · Tax withholding (F): 3,843 @ $4.23 · Option exercise (M): 9,766 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | BILINSKY IGOR — Chief Operating Officer | Option exercise (M): 7,813 @ $0 · Tax withholding (F): 3,976 @ $4.23 · Option exercise (M): 7,813 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Vogt Frederick G — Interim CEO & General Counsel, Director | Option exercise (M): 41,668 @ $0 · Tax withholding (F): 17,701 @ $3.96 · Option exercise (M): 41,668 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Puri Raj K. — Chief Regulatory Officer | Option exercise (M): 5,469 @ $0 · Tax withholding (F): 2,508 @ $3.96 · Option exercise (M): 5,469 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | GRAF FINCKENSTEIN FRIEDRICH — Chief Medical Officer | Option exercise (M): 8,790 @ $0 · Tax withholding (F): 4,473 @ $3.96 · Option exercise (M): 8,790 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | BILINSKY IGOR — Chief Operating Officer | Option exercise (M): 8,790 @ $0 · Tax withholding (F): 4,473 @ $3.96 · Option exercise (M): 8,790 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Kirby Daniel Gordon — Chief Commercial Officer | Option exercise (M): 10,000 @ $0 · Tax withholding (F): 2,435 @ $3.70 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Roche Corleen M. — Chief Financial Officer | Grant/award (A): 132,200 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Vogt Frederick G — Interim CEO & General Counsel, Director | Grant/award (A): 235,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Puri Raj K. — Chief Regulatory Officer | Grant/award (A): 117,500 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | GRAF FINCKENSTEIN FRIEDRICH — Chief Medical Officer | Grant/award (A): 58,750 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Kirby Daniel Gordon — Chief Commercial Officer | Grant/award (A): 132,200 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | BILINSKY IGOR — Chief Operating Officer | Grant/award (A): 117,500 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Vogt Frederick G — Interim CEO & General Counsel, Director | Option exercise (M): 62,493 @ $0 · Tax withholding (F): 26,755 @ $4.58 · Option exercise (M): 62,493 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | GRAF FINCKENSTEIN FRIEDRICH — Chief Medical Officer | Option exercise (M): 31,246 @ $0 · Tax withholding (F): 16,520 @ $4.58 · Option exercise (M): 31,246 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Puri Raj K. — Chief Regulatory Officer | Option exercise (M): 39,059 @ $0 · Tax withholding (F): 18,360 @ $4.58 · Option exercise (M): 39,059 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | BILINSKY IGOR — Chief Operating Officer | Option exercise (M): 31,246 @ $0 · Tax withholding (F): 16,628 @ $4.58 · Option exercise (M): 31,246 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Vogt Frederick G — Interim CEO & General Counsel, Director | Option exercise (M): 52,087 @ $0 · Tax withholding (F): 22,809 @ $3.79 · Option exercise (M): 41,669 (derivative) @ $0 · Option exercise (M): 10,418 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | BILINSKY IGOR — Chief Operating Officer | Option exercise (M): 12,307 @ $0 · Tax withholding (F): 6,903 @ $3.79 · Option exercise (M): 8,790 (derivative) @ $0 · Option exercise (M): 3,517 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Puri Raj K. — Chief Regulatory Officer | Option exercise (M): 5,470 @ $0 · Tax withholding (F): 2,798 @ $3.79 · Option exercise (M): 5,470 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | GRAF FINCKENSTEIN FRIEDRICH — Chief Medical Officer | Option exercise (M): 12,697 @ $0 · Tax withholding (F): 7,122 @ $3.79 · Option exercise (M): 8,790 (derivative) @ $0 · Option exercise (M): 3,907 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Kirby Daniel Gordon — Chief Commercial Officer | Option exercise (M): 120,000 @ $0 · Tax withholding (F): 34,165 @ $3.78 · Option exercise (M): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Kirby Daniel Gordon — Chief Commercial Officer | Option exercise (M): 39,996 @ $0 · Tax withholding (F): 16,450 @ $2.60 · Option exercise (M): 39,996 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | GRAF FINCKENSTEIN FRIEDRICH — Chief Medical Officer | Option exercise (M): 8,789 @ $0 · Tax withholding (F): 4,464 @ $2.23 · Option exercise (M): 3,906 @ $0 · Tax withholding (F): 1,984 @ $2.14 · Option exercise (M): 8,789 (derivative) @ $0 · Option exercise (M): 3,906 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | BILINSKY IGOR — Chief Operating Officer | Option exercise (M): 8,789 @ $0 · Tax withholding (F): 4,464 @ $2.23 · Option exercise (M): 3,516 @ $0 · Tax withholding (F): 1,786 @ $2.14 · Option exercise (M): 8,789 (derivative) @ $0 · Option exercise (M): 3,516 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Vogt Frederick G — Interim CEO & General Counsel, Director | Option exercise (M): 41,669 @ $0 · Tax withholding (F): 17,701 @ $2.23 · Option exercise (M): 10,417 @ $0 · Tax withholding (F): 4,426 @ $2.14 · Option exercise (M): 41,669 (derivative) @ $0 · Option exercise (M): 10,417 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Puri Raj K. — Chief Regulatory Officer | Option exercise (M): 5,469 @ $0 · Tax withholding (F): 2,467 @ $2.23 · Option exercise (M): 5,469 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | Vogt Frederick G — Interim CEO & General Counsel, Director | Option exercise (M): 52,086 @ $0 · Tax withholding (F): 22,127 @ $2.19 · Option exercise (M): 10,417 (derivative) @ $0 · Option exercise (M): 41,669 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | Puri Raj K. — Chief Regulatory Officer | Option exercise (M): 5,470 @ $0 · Tax withholding (F): 2,467 @ $2.19 · Option exercise (M): 5,470 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | GRAF FINCKENSTEIN FRIEDRICH — Chief Medical Officer | Option exercise (M): 12,697 @ $0 · Tax withholding (F): 6,448 @ $2.19 · Option exercise (M): 3,907 (derivative) @ $0 · Option exercise (M): 8,790 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | BILINSKY IGOR — Chief Operating Officer | Option exercise (M): 12,306 @ $0 · Tax withholding (F): 6,250 @ $2.19 · Option exercise (M): 3,516 (derivative) @ $0 · Option exercise (M): 8,790 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Roche Corleen M. — Chief Financial Officer | Grant/award (A): 300,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Countouriotis Athena — Director | Grant/award (A): 67,546 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Dukes Iain D. — Director | Grant/award (A): 135,092 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Maynard Ryan D — Director | Grant/award (A): 67,546 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | WEISER MICHAEL — Director | Grant/award (A): 67,546 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | YARNO WENDY L — Director | Grant/award (A): 67,546 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Kirby Daniel Gordon — Chief Commercial Officer | Purchase (P): 30,000 @ $1.84 | EDGAR |
| 2025-06-04 | 4 | Puri Raj K. — Chief Regulatory Officer | Option exercise (M): 5,469 @ $0 · Tax withholding (F): 2,467 @ $1.76 · Option exercise (M): 5,469 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Vogt Frederick G — Interim CEO & General Counsel, Director | Option exercise (M): 52,085 @ $0 · Tax withholding (F): 22,127 @ $1.76 · Option exercise (M): 10,417 (derivative) @ $0 · Option exercise (M): 41,668 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | GRAF FINCKENSTEIN FRIEDRICH — Chief Medical Officer | Option exercise (M): 12,695 @ $0 · Tax withholding (F): 6,448 @ $1.76 · Option exercise (M): 3,906 (derivative) @ $0 · Option exercise (M): 8,789 (derivative) @ $0 | EDGAR |
Recent 8-K events — IOVANCE BIOTHERAPEUTICS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-24 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IOVA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →